The parallel RECON protocol was used to generate 50 independent design simulations of antibodies with predicted increased breadth against viruses in the panel.
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G27 -P28  A28  D28  E28  P28  S28  D30  N30  A35  H35  H104  Q105  Y105  T106  F107  I107  A108  C108-C115  T108  D109  E109  E109-R111  N109  S109  P110  G111  N111  R111  T111  E112  G112  Q112  S112  T112  A114  C114  F114  H114  I114  S114  F115  Q115  R115  Y115  A116 A116-L118 G116 H116 S116 S116-T118 S116-L118 S116-D120 E117 G117 C118 E118 K118 L118 Q118 R118 R118-D120 S118 T118 V118 Y118 A120 D120 E120 H120 R120 T120 7mut 8mut HA target 1ruy 1rvx 2wrh 3hto 3lzf 3m6s 3mlh 3ubq 4eda 4edb 4f3z 4hkx 4lxv Figure S3 . Breakdown of single and double amino acid mutations in antibody C05. All mutations introduced by multistate design of antibody C05 were modeled as single point mutants, or double mutants in the case that there were complementary mutations. In addition two sets of mutation combinations were modeled (7mut and 8mut). Mutations are shown on the X axis. Y axis shows mutant fitness subtracted from wild-type fitness. Fitness is calculated as a normalized sum of antibody stability and antigen binding, expressed as a Z score. Figure S8 . Hydrogen-deuterium exchange (HDX) data of C05 V110P-A117E binding to the head domain of A/Solomon Islands/03/2006 (SI06). We measured the difference in deuterium uptake in the bound vs unbound states of both the antibody and antigen to map peptides comprising the paratope and epitope of the interaction. Peptides that were blocked from deuterium uptake upon binding mapped primarily to the CDRH3 loop of the antibody and the rim of the receptor binding domain on the antigen, in agreement with the modeling data and the co-crystal structure. Color code: yellow-green indicates no difference in deuterium uptake in bound vs unbound state. Blue indicates less deuterium uptake in bound state compared to unbound state. Blank spaces are peptides not observed in experiment.
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that were from uptake upon are in the context of the C05 V110P-A117E in y HA from the - Figure S9 . Melting curves from differential scanning fluorimetry (DSF) are shown for all C05 mutants measured. The first derivative in the melting curve was calculated (right) to assign melting transitions for domain 1 (Fc) and domain 2 (Fab). Figure S10 . Tradeoff of affinity and breadth in design against H1 strains. For each of the 13 targets in the panel, C05 was redesigned using single state design (SSD) to increase affinity, as well as multistate design (MSD) to increase breadth. We calculated the average score and binding energy for the ten best models resulting from both MSD and SSD. The points are connected by antigen, i.e. the SSD models against target PDB ID 1rvx are connected to the MSD models against target PDB ID 1rvx. The SSD models had significantly lower score (left) and binding energy (right) than the MSD models. Statistical significance was calculated using a Wilcoxon matched signed rank test in Graphpad Prism
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Bond angle ( o ) a Numbers in parentheses refer to the highest resolution shell. b Rsym = Σhkl Σi | Ihkl,i -<Ihkl> | / Σhkl Σi Ihkl,i and Rpim = Σhkl (1/(n-1)) 1/2 Σi | Ihkl,i -<Ihkl> | / Σhkl Σi Ihkl,i, where Ihkl,i is the scaled intensity of the i th measurement of reflection h, k, l, <Ihkl> is the average intensity for that reflection, and n is the redundancy. c CC1/2 = Pearson correlation coefficient between two random half datasets. d Za is the number of HA1-Fab complexes per crystallographic asymmetric unit. e Rcryst = Σhkl | Fo -Fc | / Σhkl | Fo | x 100, where Fo and Fc are the observed and calculated structure factors, respectively. f Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement. 
SI Appendix: Additional Materials and Methods
Structure preparation
To generate templates for multistate design, we downloaded structures of the influenza HA proteins and co-complex structures of influenza-binding antibodies from the PDB. The structures were processed manually to remove waters and non-protein residues. The heavy chain constant region 1 (CH1) and light chain constant region (CL) domains of antibody structures were removed from the structure manually, and the structure was renumbered starting from residue 1. The HA structures were truncated to the head domain based on the start and end residues of the structure in PDB ID 4yk4. To generate mock complexes of antibody and antigen, the antigens in the panel were aligned to the antigen in the co-crystal structure of each antibody using the structural alignment feature in PyMOL (18) . To increase diversity of designed sequences, we performed replicates of multistate design using all copies of antibodies included in the asymmetric unit of the co-crystal structure and included all output models in our analysis. All HA sequences are denoted in H3 numbering.
RECON multistate design
For inclusion in design, we considered any residue on the antibody with a heavy atom within 7 Å of a heavy atom on the HA. Residues on the HA that fulfilled the same distance cutoff were included as residues available for repacking. We ran RECON multistate design with four rounds of a ramping sequence constraint (19) . Backrub movements were performed on the backbone of the designable region of the antibody in between rounds of sequence design, to increase diversity (20) . Designed models were refined by ROSETTA relax, with constraints to the starting coordinates to prevent the backbone from making substantial movements. Constraints were placed on all Ca atoms with a standard deviation of 1.0 Å. Sequences generated by multistate design were visualized using the WebLogo tool (21) . For RECON multistate design benchmarking, we included an ensemble of 524 antibody-antigen pairs, where the antigens were homology models made by RosettaCM, each paired with antibody C05. For production runs of multistate design, 7 different antibodies were paired with a panel of 13 H1 HAs with available structures. Each multistate design run was distributed on a computing cluster such that each state (i.e., each antibody-antigen pair) was handled on its own processor. This approach resulted in distribution over 524 processors for benchmarking and 13 processors for production.
Design validation
To validate the designs introduced by multistate design, we remodeled the mutations as isolated point mutations, either with each mutation separately, or with two or three mutant combinations in the case that the mutations appeared to be complementary. Multistate design models were evaluated visually to determine which mutations were complementary. The point mutants were refined with the same protocol as previously described, using ROSETTA relax with a 1.0 Å backbone constraint to the starting coordinates. We evaluated the effect of these mutations by normalizing the total score of the antibodyantigen complex and the binding energy (DDG) to a single metric of fitness, expressed as a Z score.
DDG was defined as below:
where EAb and EAg are the energies of the antibody and antigen alone, respectively. A cutoff of 0.5 standard deviations was applied to identify candidates for expression and testing.
Homology modeling
For modeling of large panels of HA structures, we first downloaded all unique H1 HA sequences from the Influenza Research Database (22) , which yielded 8,725 sequences. To reduce this panel to a size that could be processed on our computing hardware, we clustered these sequences at 95% homology using the CD-HIT software (23) to yield 524 sequences for homology modeling. We used RosettaCM to generate homology models based on 13 H1 HA template structures (24) . The top 5 templates in sequence homology were used with the multi-template RosettaCM protocol. 250 models were generated for each HA target, and the lowest energy model was moved forward for multistate design.
Recombinant antibody expression
33 variants of antibody C05 were identified from the computational screen and prioritized for experimental characterization. Point mutants were generated using site-directed mutagenesis with the QuikChange II kit (Agilent Technologies), using the recommended protocol. Variants that incorporated multiple mutants were synthesized (Synthetic Genomics) and cloned into an Ig expression vector (25) using the Gibson Assembly Master Mix reagent (New England BioLabs). Antibody variants were expressed by transient transfection of small scale (3 mL) cultures of Expi293F human embryonic kidney cells in serum-free medium (ThermoFisher Scientific). The supernatants were harvested after 7 days, filter-sterilized with a 0.2-μm filter, and IgG concentration in supernatant was measured using the FortéBio Octet system for quantitation using anti-IgG AHQ sensors. Variants were screened for activity by loading variant IgG onto Octet anti-IgG biosensors and testing for binding to recombinant HA protein.
Variants that showed increased association in screening were expressed in Expi293F cells in a larger scale. Supernatant was harvested as described above and purified using a 5 mL HiTrap MabSelectSure protein A column (GE Healthcare).
Recombinant HA expression
Sequences encoding the HA genes of interest were optimized for expression in human cells and synthesized (Genscript). Genes were constructed as soluble trimer constructs by replacing the transmembrane and cytoplasmic domain sequences with a GCN4 trimerization domain and a 6x-His 5 tag at the C-terminus. Synthesized genes were cloned into the pcDNA3.1(+) mammalian expression vector (Invitrogen). HA protein was expressed by transient transfection of Expi293F cells (ThermoFisher Scientific). Supernatants were harvested after 7 days, filter-sterilized with a 0.2-μm filter, and purified using affinity chromatography with a 5 mL HisTrap excel column (GE Healthcare). HA head domain used for hydrogen-deuterium exchange was synthesized as a maltose-binding protein (MBP) fusion in pMAL-c5x vector (New England BioLabs). Head domain was expressed in SHuffle T7 Express competent E. coli (New England BioLabs) to enable disulfide formation in the cytoplasm, induced by the addition of 1 mM IPTG overnight at 18 °C, and purified using amylose resin (New England BioLabs).
Biolayer interferometry assay
Binding kinetics were determined using biolayer interferometry (BLI) with an Octet Red instrument (FortéBio, Menlo Park, CA). Recombinant HA proteins were labeled with biotin using an EZ-Link Sulfo-NHS-Biotin labeling kit (ThermoFisher Scientific), at a molar ratio of 1:100 protein to biotin. HAs were loaded onto streptavidin biosensors at 10 μg/mL in kinetics buffer (PBS + 1% BSA, 0.05% Tween 20).
The binding experiments were performed with the following steps: 1) baseline in kinetics buffer for 60 s, 2) loading of HA for 120-150 s, in order to achieve a response of 0.5 -1.0 nm, 3) baseline for 60 s, 4) association of antibody for 300 s, and 5) dissociation of antibody into kinetics buffer for either 3 or 20 min. A reference well with antigen loaded onto the biosensor but no antibody was run in all experiments subtracted from sample wells to correct for drift and buffer evaporation. Four dilutions of antibody were used for each binding assay. Curves were fit to a 2:1 binding model using the FortéBio software and the high affinity component of the binding model was reported. Curves were accepted if they fulfilled an R 2 of > 0.9.
ELISA binding assay
Recombinant HA was coated onto an ELISA plate (Nunc MaxiSorp flat-bottom plate, ThermoFisher Scientific) at 1 μg/mL and incubated for 1 hour at 37 °C. To reduce nonspecific binding, uncoated sites on wells were blocked with 5% milk powder (Bio-Rad) in PBS for 1 hour at 37 °C. Antibodies were diluted serially 2-fold in blocking buffer starting at 1-20 μg/mL, for a total of 12 dilutions. Antibody dilutions were incubated with the coated plate for 1 hour at 37 °C. To detect binding, plates were incubated with mouse anti-human IgG Fc-HRP secondary antibodies (Southern Biotech) for 1 hour at 37° C. Binding was detected by addition of 100 μL of TMB substrate (ThermoFisher Scientific) and incubated for 5-10 min before quenching the reaction with 100 μL of 1 N HCl. Plates were read at 450 nm using a BioTek plate reader. After plate coating and primary and secondary antibody incubation, plates were washed 3x with wash buffer (PBS +0.05% Tween 20, Cell Signaling Technologies). EC50 values were calculated in GraphPad Prism using robust nonlinear regression. Neutralization potential of the mAbs was determined by hemagglutination inhibition assay. For HAI 25 μL of four hemagglutination units of virus were incubated with 25 μL of two-fold serial dilutions of antibodies starting at 100 μg/mL in PBS for 1 hour at room temperature. The 50 μL of antibody-virus mixture was incubated with 50 μL of 0.5% turkey red blood cells (Rockland) diluted in PBS for 45 7 minutes at 4 °C. The HAI titer was defined as the highest dilution of antibody that inhibited hemagglutination of red blood cells.
Viruses and hemagglutination inhibition assay
Differential scanning fluorimetry
Differential scanning fluorimetry was performed with 50 μg/mL IgG and SYPRO orange dye (ThermoFisher Scientific) at a 1:5,000 dilution, in a total reaction volume of 25 μL. Temperature cycling was done in a BioRad CFX96 real-time PCR system (BioRad), with a temperature gradient from 25 °C to 95 °C. The temperature was ramped in increments of 0.1 °C with a hold time of 3 s, and a two-minute hold at the first and last steps. Fluorescence was detected in FRET mode. The data were imported to Prism (GraphPad Software) and, to determine the apparent melting temperatures, the peaks in the first derivative plot were calculated. All melting curves were performed with four replicates and the average value is reported.
Crystallization and structural determination
HA1 (H3 numbering: residues 43-309) from A/Hong Kong/1/1968 (HK68/H3) was expressed in insect cells as described (12) The structure was solved by molecular replacement using Phaser (27) with PDB 4FP8 (12) as the molecular replacement model, modeled using Coot (28) , and refined using Refmac5 (29) .
Ramachandran statistics were calculated using MolProbity (30) . 
Hydrogen-deuterium exchange mass spectrometry
